ライフサイエンスコーパス: endophthalmitis

1 hthalmitis, and change in VA 12 months after endophthalmitis.

2 g retinal innate responses in staphylococcal endophthalmitis.

3 fragments, retinal detachment, and suspected endophthalmitis.

4 ics was not associated with a higher risk of endophthalmitis.

5 patients (85.7%) with post-cataract surgery endophthalmitis.

6 tes mellitus, are particularly more prone to endophthalmitis.

7 a statistically significant association with endophthalmitis.

8 ery-related intraoperative complications and endophthalmitis.

9 causes of post-operative and post-traumatic endophthalmitis.

10 factors, and prophylaxis methods related to endophthalmitis.

11 f follow-up when compared with acuity before endophthalmitis.

12 One eye in the ranibizumab group developed endophthalmitis.

13 demonstrated evidence of chorioretinitis or endophthalmitis.

14 ting an important role for TLR4 in B. cereus endophthalmitis.

15 ere diagnosed with fungal chorioretinitis or endophthalmitis.

16 blebitis, endophthalmitis, or blebitis with endophthalmitis.

17 ly associated with a diagnosis of endogenous endophthalmitis.

18 more likely to be diagnosed with endogenous endophthalmitis.

19 e factors associated with the development of endophthalmitis.

20 re center followed by blind painful eyes and endophthalmitis.

21 r a pathogenic mechanism in culture-negative endophthalmitis.

22 or blebitis and 5.0% (95% CI, 1.0%-9.0%) for endophthalmitis.

23 lementary information in presumed infectious endophthalmitis.

24 jection does not seem to reduce the risk for endophthalmitis.

25 ant role for these TLR adaptors in B. cereus endophthalmitis.

26 contributed to inflammation during B. cereus endophthalmitis.

27 were no cases of intraocular inflammation or endophthalmitis.

28 an extremely rare presentation of metastatic endophthalmitis.

29 0.007) were associated with a higher rate of endophthalmitis.

30 The primary outcome was the development of endophthalmitis.

31 al pars plana vitrectomy due to postcataract endophthalmitis.

32 the 5 to 7 days expected for acute bacterial endophthalmitis.

33 condary infectious scleritis, and infectious endophthalmitis.

34 s complications, such as lens subluxation or endophthalmitis.

35 ated with a trend toward higher incidence of endophthalmitis.

36 wenty patients had chorioretinitis and 2 had endophthalmitis.

37 There were no cases of fungal endophthalmitis.

38 e excellent empiric antibiotics for treating endophthalmitis.

39 ains the most frequently identified cause of endophthalmitis.

40 risk for eye infections including bacterial endophthalmitis.

41 topics in the prophylaxis and management of endophthalmitis.

42 ical management and outcomes of each case of endophthalmitis.

43 tic rabbit model of Streptococcus pneumoniae endophthalmitis.

44 ic choice for the treatment of Gram-positive endophthalmitis.

45 inical outcomes associated with each case of endophthalmitis.

46 be necessary in all cases of DEX-associated endophthalmitis.

47 hen and now) in prevention and management of endophthalmitis.

48 yes) (P = 0.6), and no patient had bilateral endophthalmitis.

49 l complication remains a key risk factor for endophthalmitis.

50 tic period, there were 11 cases of suspected endophthalmitis (0.032%; 1 in 3173 injections), 4 of whi

51 tic period, there were 28 cases of suspected endophthalmitis (0.049%; 1 in 2059 injections), 10 of wh

52 We confirmed 215 cases of endophthalmitis (0.07% or 0.7/1000).

53 24.1%, P = .0007), a higher association with endophthalmitis (11.8% vs 0%, P = .03), previous history

54 avitreal injection (2/19, 10.5%), endogenous endophthalmitis (2/19, 10.5%), post-pars plana vitrectom

55 glaucoma (19 %) in the enucleation group and endophthalmitis (28.6 %) in the evisceration group.

56 elt (5 eyes), infectious keratitis (3 eyes), endophthalmitis (3 eyes), GDD erosion (2 eyes), and reti

57 We found 71 cases of endophthalmitis (49 in the bevacizumab cohort and 22 in

58 endophthalmitis was 10.6 with a 9.4% rate of endophthalmitis (5 cases per 53 injections).

59 Among 42 patients with postinjection endophthalmitis, 5 (11.9%) did not receive PI prophylaxi

60 retinopathy of prematurity (12 [17.6%]), and endophthalmitis (6 [8.8%]).

61 significant association with development of endophthalmitis after a bevacizumab injection compared w

62 The odds of developing endophthalmitis after an intravitreal injection of bevac

63 The incidence of endophthalmitis after cataract surgery in our center was

64 The overall rate of endophthalmitis after cataract surgery was 0.14% in 216

65 ty (VA) outcomes associated with acute-onset endophthalmitis after clear corneal cataract surgery ove

66 possible to monitor the trend of infectious endophthalmitis after corneal transplant or cataract sur

67 Two patients had culture-proven bacterial endophthalmitis after DEX monoinjections (0.06% of injec

68 re reviewed to identify patients treated for endophthalmitis after injection during the same time per

69 The incidence of endophthalmitis after intravitreal injection is low.

70 erm outcomes of infectious and noninfectious endophthalmitis after intravitreal injections (IVTs) of

71 The incidence of presumed endophthalmitis after intravitreal injections of anti-va

72 e incidences of infectious and noninfectious endophthalmitis after IVT were low, and the risk did not

73 3593 injections of DEX, 4 patients developed endophthalmitis; all 4 patients were white, female, and

74 Endophthalmitis, an infection and inflammation of the po

75 Literature reviews for compounding-related endophthalmitis and drug counterfeiting were performed.

76 y by PPV may be preferred to identify fungal endophthalmitis and facilitate prompt diagnosis and trea

77 Most postkeratoplasty endophthalmitis and keratitis cases are now of a fungal

78 1 patient had additional novel features (eg, endophthalmitis and osteomyelitis).

79 on rare complications such as postoperative endophthalmitis and outcomes from uncommon procedures su

80 a mouse model of Staphylococcus aureus (SA) endophthalmitis and performing retinal transcriptome ana

81 acute (<40 days) or delayed-onset (40+ days) endophthalmitis and risk of a new primary open-angle gla

82 Cumulative rate of endophthalmitis and survival curves were measured using

83 come measures were the incidence of clinical endophthalmitis and visual acuity of endophthalmitis cas

84 One patient developed bacterial endophthalmitis and was excluded from analyses.

85 associated with a low rate of postinjection endophthalmitis and was well tolerated by patients.

86 Incidence and cumulative rate of endophthalmitis, and change in VA 12 months after endoph

87 l melts resulting from exposure keratopathy, endophthalmitis, and infectious keratitis or corneal ulc

88 There were no cases of endophthalmitis, and the total incidence of Anti-Platele

89 Acute postoperative endophthalmitis (APE) is a serious, although infrequent,

90 fungal isolates from culture-positive fungal endophthalmitis are reported.

91 ffusion, choroidal hemorrhage, blebitis, and endophthalmitis, as they relate to the mitomycin concent

92 owledge, the optimal management of eyes with endophthalmitis associated with DEX has not been establi

93 Cases of endophthalmitis associated with DEX were also identified

94 lculated and compared for each definition of endophthalmitis at 6-week and 6-month intervals after co

95 treated for culture-proven exogenous fungal endophthalmitis at a university referral center from 199

96 guishing sterile inflammation and infectious endophthalmitis at the time of presentation may often be

97 The combined rate of postinjection endophthalmitis at these 2 centers was 0.019%.

98 ptibility of Gram-positive and Gram-negative endophthalmitis bacterial isolates to vancomycin, amikac

99 idal thickness decreased significantly after endophthalmitis, but there was no functional correlation

100 Symptoms of fungal endophthalmitis can be minimal and delayed long beyond t

101 The delayed presentation of endophthalmitis cases also raises questions regarding po

102 One hundred twelve endophthalmitis cases among 480 104 operations reported,

103 We identified endophthalmitis cases occurring after cataract surgery u

104 ifloxacin prophylaxis and treatment of the 6 endophthalmitis cases.

105 linical endophthalmitis and visual acuity of endophthalmitis cases.

106 Endophthalmitis caused by Bacillus cereus develops as ac

107 inolone or other medications of the risk for endophthalmitis caused by Bipolaris hawaiiensis-contamin

108 trospectively reviewed for all patients with endophthalmitis caused by Corynebacterium species from J

109 reatment, and visual acuity (VA) outcomes of endophthalmitis caused by Corynebacterium species.

110 Patients with endophthalmitis caused by Corynebacterium species.

111 Endophthalmitis caused by Curvularia is a rare condition

112 Endophthalmitis caused by nontuberculous mycobacterium o

113 ch, may be considered for empiric therapy of endophthalmitis caused by yeast or mold.

114 complications occurred, including bacterial endophthalmitis, choroidal detachment, and retinal detac

115 ssociated with a 3.68-fold increased risk of endophthalmitis (CI, 1.89-7.20).

116 l records were then reviewed to evaluate the endophthalmitis clinical features and treatment outcomes

117 We report a case of metastatic endophthalmitis combined with subretinal abscess with su

118 red a significantly increased OR of 6.92 for endophthalmitis compared with anti-VEGF agents.

119 associated with a 40% to 50% reduced odds of endophthalmitis compared with no prophylaxis (P = 0.2).

120 develop appropriate treatment guidelines of endophthalmitis complicated with subretinal abscess.

121 Since TLR2 plays an important role in SA endophthalmitis, counter regulation analysis of TLR2 lig

122 evacizumab group included 1 participant with endophthalmitis (culture negative), 9 with IOP more than

123 Endophthalmitis developed after 11 of 18 509 injections

124 Three other cases of endophthalmitis developed after coinjection with bevaciz

125 Noninfectious endophthalmitis developed in 11 of 88 150 injections (1/

126 Infectious endophthalmitis developed in 18 of 88 150 injections (1/

127 Fungal endophthalmitis developed in 82% (14/17) of eyes after i

128 antibiotic drops does not reduce the risk of endophthalmitis developing and is associated with a tren

129 niae and Coagulase negative Staphylococci in endophthalmitis diagnoses.

130 Endophthalmitis was defined as having a new endophthalmitis diagnosis (International Classification

131 However, the "risk" of infectious endophthalmitis did not increase with each successive in

132 Endophthalmitis did not influence the visual outcome.

133 d to have blebitis and 9 eyes presented with endophthalmitis during the follow-up period of 5.4 +/- 3

134 is a known risk factor for endogenous fungal endophthalmitis (EFE), a severe intraocular infection ca

135 The onset of signs and symptoms of endophthalmitis (eg, decreased vision, anterior chamber,

136 Endogenous endophthalmitis, extra-hepatic metastasis from liver abs

137 present the case of a 74-year-old woman with endophthalmitis followed by meningoencephalitis.

138 mL) has been reported to reduce the risk of endophthalmitis following cataract surgery.

139 Development of endophthalmitis following DEX and the clinical managemen

140 However, given the rarity of endophthalmitis following DEX and the heterogeneity amon

141 The rate of endophthalmitis following dexamethasone intravitreal imp

142 Endophthalmitis following intravitreal bevacizumab, rani

143 The rate of endophthalmitis for bevacizumab was 0.039% (60/153 812),

144 The management of endophthalmitis from different etiologies, including end

145 with persistently vitreous culture-positive endophthalmitis had poor visual outcomes.

146 Though chronic, post-operative endophthalmitis has been associated with most intraocula

147 2.29; 95% CI, 1.001-5.22) and delayed-onset endophthalmitis (HR, 3.65; 95% CI, 1.65-8.05).

148 plication, which included sterile vitreitis, endophthalmitis, hypotony maculopathy, suprachoroidal he

149 response observed in experimental B. cereus endophthalmitis, identifying a novel innate immune inter

150 povidone-iodine; both participants developed endophthalmitis in 1 eye.

151 We confirmed 1 case of postoperative endophthalmitis in 10 494 ISBCS eyes (1.0 per 10 000 eye

152 s within 2 lines of the visual acuity before endophthalmitis in 5 eyes (45%).

153 ophthalmitis was within +/-2 lines of before endophthalmitis in 53% and 75% of eyes, respectively; a

154 tachment in 18.8% (9 of 48 eyes), infectious endophthalmitis in 6.3% (3 of 48 eyes), and choroidal de

155 rst reported case of chronic, post-operative endophthalmitis in a patient with an iris prosthesis.

156 To report the incidence of culture-proven endophthalmitis in a single vitreoretinal practice over

157 cians should suspect chronic, post-operative endophthalmitis in any case of recurrent, low-grade intr

158 eaks of sterile and infectious postinjection endophthalmitis in at least 3 countries during the past

159 total cost of treating the 30 patients with endophthalmitis in group 1 was virtually identical to th

160 gnificant, 4-fold reduction in postoperative endophthalmitis in patients undergoing M-SICS.

161 tial predictors/comorbidities for developing endophthalmitis in patients with hematogenous infections

162 lerated dose was 1.0 mg because of a case of endophthalmitis in the 2.0 mg cohort.

163 may be associated with either vitrectomy or endophthalmitis in the history.

164 a on the microbiology of acute postoperative endophthalmitis in the United States after cataract surg

165 0.0074% (1 in 13 512) per-injection rate of endophthalmitis in this series compares favorably with p

166 cefuroxime was 100% effective in preventing endophthalmitis in this series.

167 idual inflammation observed during B. cereus endophthalmitis in TLR2(-/-) mice led us to investigate

168 was identified in eight cases (38.09 %) and endophthalmitis, in six cases (28.57 %).

169 The infectious endophthalmitis incidence rates ranged from 0.11% to 1.0

170 e 19 study patients, the clinical setting of endophthalmitis included post-cataract surgery (7/19, 36

171 yses revealed the major pathways impacted in endophthalmitis includes: metabolism, inflammatory/immun

172 ients with a history of RD or retinal break, endophthalmitis, intravitreal injection, choroidal retin

173 tory study of isolates from exogenous fungal endophthalmitis, intravitreal voriconazole appears to pr

174 Postoperative endophthalmitis is a potentially sight-threatening compl

175 Endophthalmitis is a rare but sight-threatening infectio

176 These data suggest that endophthalmitis is a rare event following injection of D

177 Post-operative endophthalmitis is a serious complication of intraocular

178 Despite advances over the past 100 years, endophthalmitis is an important sight-threatening compli

179 Endogenous endophthalmitis is associated with Klebsiella pneumoniae

180 Chronic post-operative endophthalmitis is characterized by decreased visual acu

181 It is unclear whether the severity of endophthalmitis is greater in these patients due to conf

182 Endogenous endophthalmitis is rare among hospitalized patients in t

183 abases as long as a consistent definition of endophthalmitis is used.

184 , Candida glabrata, and Candida parapsilosis endophthalmitis isolates were each inoculated into optis

185 retained vision within 10 letters of the pre-endophthalmitis level.

186 eloped endophthalmitis were ascertained from endophthalmitis logs and billing records.

187 Exclusion occurred for any history of endophthalmitis, <6 months in the plan, or <1 month foll

188 studies leading to changes in strategies for endophthalmitis management over the last 100 years.

189 Chronic, post-operative endophthalmitis may be a difficult to identify in the co

190 istry in eyes with and without postoperative endophthalmitis measured 1-7 days postoperatively were l

191 After exclusions (any previous diagnosis of endophthalmitis, multiple injected drugs given on the in

192 omplications included hyphema (n = 3; 6.8%), endophthalmitis (n = 1; 2.3%), wound leak (n = 1; 2.3%),

193 rrhage (n = 10), vitreous opacities (n = 8), endophthalmitis (n = 4), sub-silicone oil retinal detach

194 ens (n = 10), submacular hemorrhage (n = 7), endophthalmitis (n = 6), and retained lens material (n =

195 erval between injection and presentation for endophthalmitis nor the clinical signs differentiated cu

196 Acute postoperative endophthalmitis occurred in 1 case (0.26%).

197 Endophthalmitis occurred in 14 of 17 eyes, the first pre

198 No endophthalmitis occurred in this series.

199 ) performed with povidone-iodine, 9 cases of endophthalmitis occurred: 6 cases (0.05% of 11565 inject

200 Eleven cases of endophthalmitis occurred; 4 occurred between 2012 and 20

201 The overall incidence of endophthalmitis occurring after primary PK in the UK was

202 e, race, and gender, the odds ratio (OR) for endophthalmitis occurring was 6.92 (95% confidence inter

203 between 2006 and 2015 with culture-positive endophthalmitis occurring within 6 weeks of clear cornea

204 The incidence of endophthalmitis occurring within 6 weeks of surgery was

205 Therefore, if endophthalmitis occurs post-operatively, the source may

206 h a trend toward increased risk of suspected endophthalmitis (odds ratio [OR], 1.54; 95% confidence i

207 One patient developed endophthalmitis on 2 separate occasions.

208 Wound dehiscence, endophthalmitis or retinal detachment was not observed.

209 e in the rates of KPro extrusion (P = 0.41), endophthalmitis or vitritis (P = 0.15), retinal detachme

210 R = 5.167, 95% CI: 2.194-23.150, p = 0.003), endophthalmitis (OR = 2.167, 95% CI: 1.234-13.140, p = 0

211 terval [CI], 0.77-3.10) and culture-positive endophthalmitis (OR, 1.51; 95% CI, 0.47-4.83).

212 related infections were defined as blebitis, endophthalmitis, or blebitis with endophthalmitis.

213 implant migration into the anterior chamber, endophthalmitis, or retinal detachment.

214 There was no case of endophthalmitis, orbital dissemination, local recurrence

215 or between the injection and a diagnosis of endophthalmitis), our analysis involved 383810 intravitr

216 e analysis on isolates from a 2012 Bipolaris endophthalmitis outbreak caused by a contaminated produc

217 ironmental sources while confirming that the endophthalmitis outbreak resulted from a point source, w

218 2 (0.02%) were diagnosed with postoperative endophthalmitis (P < 0.0001).

219 ly associated with an increased incidence of endophthalmitis (P = .001).

220 Endophthalmitis patients that were culture positive for

221 The cumulative rate of noninfectious endophthalmitis per patient was 0.087% and 0.228% after

222 mmended as prophylaxis against postoperative endophthalmitis (POE) following cataract surgery.

223 Postoperative endophthalmitis (POE) often results in severe visual imp

224 The rate of endophthalmitis post-intravitreal steroid injection in a

225 with previous ocular surgery, postoperative endophthalmitis, postoperative retinal detachment, reope

226 All cases of presumed injection-related endophthalmitis presenting to the Massachusetts Eye and

227 common posterior segment complications were endophthalmitis (range, 0%-12.5%; mean +/- SD, 4.6+/-4.6

228 In the IRIS Registry the endophthalmitis rate after cataract surgery was 0.08% am

229 ed cases, it remains unclear whether the DEX endophthalmitis rate approximates that of intravitreous

230 To compare the postoperative endophthalmitis rate before and after initiation of intr

231 moxifloxacin prophylaxis reduced the overall endophthalmitis rate by 3.5-fold (3-fold for M-SICS and

232 Without IC moxifloxacin, PCR increased the endophthalmitis rate nearly 7-fold to 0.48% (20/4186); I

233 ort and 22 in the ranibizumab cohort) for an endophthalmitis rate of 0.017% (95% CI, 0.012%-0.021%; 1

234 For the 414 657 M-SICS eyes, the endophthalmitis rate was 0.07% (135/192 149) without IC

235 The group 3 endophthalmitis rate was 0.07% (29 eyes), which was also

236 or the 194 252 phacoemulsification eyes, the endophthalmitis rate was 0.07% (75/104 894) without IC m

237 0.48% (20/4186); IC moxifloxacin reduced the endophthalmitis rate with PCR to 0.21% (9/4293) (P = 0.0

238 , and there was a significant decline in the endophthalmitis rate, from 0.07% (214/302 815) to 0.02%

239 The postoperative endophthalmitis rates before and after initiation of IC

240 Endophthalmitis rates before and after moxifloxaxin were

241 Importance: This report provides updated endophthalmitis rates for eyes receiving intravitreous i

242 Endophthalmitis rates tended to be higher in eyes with c

243 Overall endophthalmitis rates were 0.52 (control) and 0.22 (IAI)

244 groups were analyzed, and the postoperative endophthalmitis rates were statistically compared.

245 Bacterial endophthalmitis remains a devastating inflammatory condi

246 Endophthalmitis remains a serious issue, with those affe

247 =0.13% or 1/778 steroid injections) cases of endophthalmitis, respectively.

248 s and two thirds of cases with noninfectious endophthalmitis retained vision within 10 letters of the

249 d donor risk factors are important to reduce endophthalmitis risk.

250 The majority of culture-negative endophthalmitis samples did not contain significant leve

251 No cases of postoperative endophthalmitis, sclerotomy-related retinal tears, or ch

252 Laboratory records of bacteria isolated from endophthalmitis specimens collected from January 1(st) 1

253 tive for preventing post-cataract extraction endophthalmitis than topical antibiotic alone.

254 United States does not increase the risk for endophthalmitis; therefore, additional regulations on th

255 Historically, 3 endophthalmitis time-periods have existed and include th

256 o susceptibilities of bacteria cultured from endophthalmitis to vancomycin (VAN), amikacin (AMK), and

257 The cost of endophthalmitis treatment (groups 1 and 2) and the cost

258 mong 15 eyes with blebitis, 2 eyes developed endophthalmitis under treatment.

259 The main outcome measure was the odds of endophthalmitis using logistic regression while controll

260 age is higher than that recommended from the Endophthalmitis Vitrectomy Study, with no evidence of in

261 verall incidence rate of presumed endogenous endophthalmitis was 0.05%-0.4% among patients with funge

262 Incidence of endophthalmitis was 0.15% among injections with no antib

263 ections without PI before the development of endophthalmitis was 10.6 with a 9.4% rate of endophthalm

264 Graft survival after endophthalmitis was 27% (95% confidence interval, 16-38)

265 from surgical procedure to presentation with endophthalmitis was 6.8 months (range: 1 day to 28 month

266 e mean time between surgery and diagnosis of endophthalmitis was 8 days (median 6 days).

267 Persistently culture-positive fungal endophthalmitis was associated with poor final visual ac

268 Endophthalmitis was defined as having a new endophthalmi

269 The incidence of endophthalmitis was determined from August 1, 2011, to F

270 c prophylaxis (route and agent) with risk of endophthalmitis was estimated using logistic regression

271 Treatment for presumed bacterial endophthalmitis was given initially in 14 patients (88%)

272 The incidence of noninfectious endophthalmitis was higher for bevacizumab (8/9931, 0.08

273 The rate of endophthalmitis was lower if a fluoroquinolone was used

274 In contrast, endophthalmitis was more likely to occur if timolol was

275 e patients was performed to confirm that the endophthalmitis was related to the antecedent anti-VEGF

276 In cases where endophthalmitis was reported, the diagnosis was verified

277 No endophthalmitis was reported.

278 e 0.05% or 0.1% for prophylaxis of infective endophthalmitis was undertaken.

279 12-month VA in infectious and noninfectious endophthalmitis was within +/-2 lines of before endophth

280 Cases of endophthalmitis were acquired using a detailed, prospect

281 Patients who developed endophthalmitis were ascertained from endophthalmitis lo

282 Incidence rates of endophthalmitis were calculated and compared for each de

283 Patients with endophthalmitis were culture positive for bacteria in 66

284 7%) from eyes harboring suspected infectious endophthalmitis were culture-positive, the most common b

285 Factors associated with endophthalmitis were donor cause of death (infection), h

286 Demographic risk factors for endophthalmitis were examined using multivariate Cox mod

287 uring the study period, 65 cases of presumed endophthalmitis were found, giving an overall incidence

288 hematogenous infections, odds of endogenous endophthalmitis were higher for children and middle-aged

289 Patients who developed endophthalmitis were identified on the transplant regist

290 Three cases of endophthalmitis were identified with 1 culture-positive

291 e included, from which 183 cases of presumed endophthalmitis were identified.

292 ulture-proven or clinical evidence of fungal endophthalmitis were included.

293 Rates of endophthalmitis were low and similar to those in other l

294 , and cases involving legal blindness and/or endophthalmitis were more likely to be resolved in favor

295 No cases of endophthalmitis were observed among the 25 920 patients

296 vides further evidence regarding the risk of endophthalmitis when povidone-iodine is not used before

297 In particular, the increased incidence of endophthalmitis when the donor dies of infection require

298 We found higher rates of noninfectious endophthalmitis with bevacizumab compared with ranibizum

299 hirty-six eyes of 36 patients with exogenous endophthalmitis with the same bacterial organism identif

300 at intraocular inflammation during B. cereus endophthalmitis would be controlled by MyD88- and TRIF-m